首页> 外文期刊>The annals of pharmacotherapy >Azithromycin-Induced Proarrhythmia and Cardiovascular Death
【24h】

Azithromycin-Induced Proarrhythmia and Cardiovascular Death

机译:阿奇霉素引起的心律失常和心血管死亡

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To review the possible association between azithromycin and increased cardiovascular risk. Data sources: A literature search of MEDLINE (1946-August 2013) was performed using the search terms macrolide, azithromycin, QT prolongation, cardiovascular, and torsade de pointes. Additional references were identified from a review of literature citations. Study selection and data extraction: All English-language observational studies assessing the association between azithromycin and QT prolongation or cardiovascular risk were evaluated. Case reports describing this potential association were also reviewed. Data synthesis: A total of 6 case reports have shown a possible association between azithromycin and QT prolongation. In 3 of these cases, proarrhythmic events were reported. In a prospective observational study of 47 individuals with low cardiovascular risk, electrocardiograms were compared before and after 5 days of azithromycin treatment. Mild prolongation of the QTc was noted, but it was statistically insignificant compared with baseline. No arrhythmias were observed. A large observational cohort study found a small increase in cardiovascular deaths after azithromycin therapy, primarily among patients with high baseline cardiovascular risk. Conversely, a second cohort study involving a population of young to middle-aged adults failed to find an association. Conclusions: An emerging body of evidence suggests that azithromycin therapy may prolong the QT interval and, in rare cases, precipitate the potentially fatal arrhythmia torsade de pointes. Patients with additional risk factors for QT prolongation appear to be at highest risk, including women, elderly individuals; those with existing or prior history of cardiovascular disease, QT interval prolongation, hypokalemia, hypomagnesium, or bradycardia; and those using concomitant drugs associated with QT prolongation. For patients without these additional risk factors, azithromycin appears to be relatively safe.
机译:目的:探讨阿奇霉素与心血管风险增加之间的可能关联。数据来源:使用大环内酯类,阿奇霉素,QT延长,心血管和尖峰扭转的检索词对MEDLINE(1946-2013年8月)进行文献检索。其他参考文献是从文献引用文献中查到的。研究选择和数据提取:评估了所有评估阿奇霉素与QT延长或心血管风险之间关系的英语观察性研究。还审查了描述这种潜在关联的病例报告。数据综合:总共6例病例报告显示阿奇霉素与QT延长之间可能存在关联。在其中3例中,报告了心律失常事件。在一项前瞻性观察性研究中,对47名具有低心血管风险的个体进行了研究,比较了阿奇霉素治疗5天之前和之后的心电图。注意到QTc的轻微延长,但与基线相比在统计学上不显着。没有观察到心律不齐。一项大规模的观察性队列研究发现,阿奇霉素治疗后心血管死亡的增加很小,主要是在基线心血管风险高的患者中。相反,第二项涉及年轻人和中年成年人群的队列研究未能找到关联。结论:越来越多的证据表明,阿奇霉素治疗可能会延长QT间隔,在极少数情况下,会加剧潜在的致命性心律失常。患有QT延长的其他危险因素的患者似乎是最高的风险,包括女性,老年人。已有或先前有心血管疾病史,QT间期延长,低钾血症,低镁或心动过缓的患者;以及那些使用与QT延长相关的药物的人。对于没有这些其他危险因素的患者,阿奇霉素似乎相对安全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号